Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 5/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | GJA1 | P17302 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.38 |
| ▸ | CDC25B | P30305 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13557604 | 0.98 | CD209 (0.47) | CD209GJB2LGALS3GJA1SLC6A2 | |
| SCHEMBL13557611 | 0.89 | LGALS3 (0.47) | CD209GJB2LGALS3GJA1SLC6A2 | |
| SCHEMBL25964138 | 0.88 | LGALS3 (0.44) | GJB2LGALS3GJA1SSTR1SSTR2 | |
| SCHEMBL15883027 | 0.87 | GJB2 (0.42) | CD209GJB2LGALS3GJA1SLC6A2 | |
| SCHEMBL13557609 | 0.86 | NT5E (0.42) | GJB2LGALS3SSTR1SSTR2SSTR4 | |
| SCHEMBL19682250 | 0.86 | CD209 (0.45) | CD209GJB2LGALS3SLC6A2SSTR1 | |
| SCHEMBL25270558 | 0.84 | LGALS3 (0.48) | CD209GJB2LGALS3SLC6A2SSTR1 | |
| SCHEMBL20648775 | 0.84 | LGALS3 (0.48) | CD209GJB2LGALS3SLC6A2SSTR1 | |
| SCHEMBL21258926 | 0.84 | CD209 (0.45) | CD209GJB2LGALS3SLC6A2SSTR1 | |
| SCHEMBL13557582 | 0.82 | SSTR1 (0.41) | GJB2LGALS3SSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | CETP, LCAT, LIPA | CD209 329/4885GJB2 3029/4885LGALS3 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.